"GLP-1 Diabetes Drug Slows Parkinson's Progression in Promising Trial"
A diabetes drug, lixisenatide, has shown potential in slowing the progression of motor issues associated with Parkinson's disease in a clinical study. The drug, which belongs to a class of drugs called GLP-1 receptor agonists, demonstrated a modest effect in preventing worsening of movement symptoms in patients with early-stage Parkinson's. However, gastrointestinal side effects were common, and further research is needed to confirm its safety and efficacy before it can be considered for widespread use.